Mechanisms of TRAIL-induced apoptosis in leukemic plasmacytoid dendritic cells

Blum, Ariane; Chaperot, Laurence; Molens, Jean-Paul; Foissaud, Vincent; Plantaz, Dominique; Plumas, Joël

doi:10.1016/j.exphem.2006.08.002

Cited by 20 publications

(19 citation statements)

References 38 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…For the experiment, the in vitrocultured human plasmacytoid DC line CNCM I-2938=GEN2.2, kindly provided by Dr. Chaperot (La Tronche, France), was used. 13,14 This cell line was developed by Dr Plumas and colleges at the Department of Research and Development, Etablissement Francais du Sang Rhone-Alpes Grenoble. Based on the difficult generation of DCs and their instability with different expression of DC markers, we used GEN2.2.…”

Section: Real-time Polymerase Chain Reaction In a Human Plasmacytoid mentioning

confidence: 99%

Expression of Circulatory Dendritic Cells and Regulatory T-Cells in Patients With Different Subsets of Coronary Artery Disease

Kofler

Sisic

Shvets

et al. 2011

Journal of Cardiovascular Pharmacology

View full text Add to dashboard Cite

show abstract

Section: Real-time Polymerase Chain Reaction In a Human Plasmacytoid mentioning

confidence: 99%

Expression of Circulatory Dendritic Cells and Regulatory T-Cells in Patients With Different Subsets of Coronary Artery Disease

Kofler

Sisic

Shvets

et al. 2011

Journal of Cardiovascular Pharmacology

View full text Add to dashboard Cite

show abstract

“…TNF-related apoptosis-inducing ligand (TRAIL) is a transmembrane protein expressed on effector cells and induces apoptosis of leukemic pDCs upon binding to DR4 and DR5 receptors, which are not expressed on normal DCs (20).TRAILdependent apoptosis involves the extrinsic pathway with caspase 8 and 10 acting as initiator caspases. Nur77 family and DC apoptosis.…”

Section: Regulation Of DC Apoptosismentioning

confidence: 99%

Dendritic Cell Apoptosis: Regulation of Tolerance versus Immunity

Kushwah

2010

The Journal of Immunology

View full text Add to dashboard Cite

Dendritic cell (DC) apoptosis is an important event that regulates the balance between tolerance and immunity through multiple pathways, and defects in DC apoptosis can trigger autoimmunity. DC apoptosis is also associated with immunosuppression and has been observed under several pathologies and infections. Recent studies indicate that apoptotic DCs can also play an active role in induction of tolerance. This review discusses the regulatory pathways of DC apoptosis, stimuli inducing DC apoptosis, and the implications of DC apoptosis in the induction of immunosuppression and/or tolerance.

show abstract

“…The potential therapeutic use of TRAIL has been also explored in the therapy of refractory diffuse large B-cell lymphoma (DLBCL) [96], plasmacytoid dendritic cell (PDC) leukaemia [97], which shows a particularly aggressive clinical course, cutaneous T-cell lymphoma (CTCL) [98] and mantle B cell lymphoma (MCL) [99]. In particular, Cillessen et al [96] have shown that 12 out of a total of 22 DLBCL samples, including 7 clinically chemotherapy-refractory lymphomas, were sensitive to TRAIL-mediated apoptosis.…”

Section: Lymphoid Malignanciesmentioning

confidence: 99%

A Combined Approach with Rituximab Plus Anti-TRAIL-R Agonistic Antibodies for the Treatment of Haematological Malignancies

Sancilio

Grill²,

Pietro

2008

CPD

View full text Add to dashboard Cite

Molecular targeted therapies have changed the landscape of cancer research. Agonistic monoclonal antibodies (MoAbs) targeting TRAIL-death receptors (TRAIL-Rs) have been developed and currently used in clinical trials. Binding of such antibodies to TRAIL-R1 and TRAIL-R2 results in death inducing signalling complex (DISC) formation and induction of apoptosis, which represents a natural mechanism of cell growth control and an ideal target for drug development. These novel fully humanized compounds have been associated with conventional chemotherapy in the treatment of advanced solid malignancies, including different types of lymphoma. Here we outline the rationale and potential of a new molecular-based strategy combining agonistic anti-TRAIL-death receptor monoclonal antibodies plus the pioneer of the new biological frontiers of cancer therapy: rituximab.

show abstract

Mechanisms of TRAIL-induced apoptosis in leukemic plasmacytoid dendritic cells

Cited by 20 publications

References 38 publications

Expression of Circulatory Dendritic Cells and Regulatory T-Cells in Patients With Different Subsets of Coronary Artery Disease

Expression of Circulatory Dendritic Cells and Regulatory T-Cells in Patients With Different Subsets of Coronary Artery Disease

Dendritic Cell Apoptosis: Regulation of Tolerance versus Immunity

A Combined Approach with Rituximab Plus Anti-TRAIL-R Agonistic Antibodies for the Treatment of Haematological Malignancies

Contact Info

Product

Resources

About